Of course, there are countless value stocks that are worth mentioning, but this is a concise list of the top 3 undervalued ...

Alkermes has reported another phase 2 win for its narcolepsy drug candidate, succeeding where Takeda failed to maintain its ...

Alixorexton’s Phase II performance sets it up for late-stage success, according to analysts at Truist Securities. Alkermes ...

Alkermes plc’s placebo-controlled phase II study of alixorexton in treating narcolepsy type 2 (NT2) hit its dual primary endpoints, producing statistically significant and clinically meaningful ...

As a comedy writer and person living with narcolepsy, I can tell you — there's nothing funny about it,' writes an L.A. Times reader.

Alkermes' experimental drug significantly improved wakefulness and reduced excessive sleepiness in patients with a rare sleep disorder in a mid-stage study, it said on Wednesday. The company was ...

Takeda has said it intends to move quickly ahead with regulatory filings for oveporexton, its orexin agonist for sleep disorder narcolepsy, after a clean sweep of positive efficacy data in two phase 3 ...

Alkermes has reached an agreement to buy Avadel Pharma in a deal valued at up to $2.1 billion, claiming rights to an FDA-approved therapy for sleep disorder narcolepsy that has been predicted to make ...